🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Moderately to Severely Active Crohn's Disease

A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease NCT05837897Phase 341 sites📍 Hefei📍 Wuhu📍 Beijing Takeda · Tests: Vedolizumab IV, Placebo A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) NCT04779320Phase 396 sites📍 Phoenix📍 Los Angeles📍 San Diego Takeda · Tests: Vedolizumab IV An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease NCT07184931Phase 3461 sites📍 Peoria📍 Scottsdale📍 Scottsdale Sanofi · Tests: Duvakitug, Placebo A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease NCT05995353Phase 385 sites📍 Phoenix📍 Little Rock📍 Oakland AbbVie · Tests: Risankizumab, Risankizumab A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease NCT07483073Phase 270 sites📍 Scottsdale📍 Los Angeles📍 Oxnard Eli Lilly and Company · Tests: Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC), LY4395089 A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD) NCT06764615Phase 216 sites📍 Glen Burnie📍 Tyler📍 Chongqing Takeda · Tests: Zasocitinib Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's Disease NCT07078994Phase 220 sites📍 Barnaul📍 Ufa📍 Moscow Biocad · Tests: anti-TL1A monoclonal antibody, low dose, anti-TL1A monoclonal antibody, medium dose, anti-TL1A monoclonal antibody, hig… A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease NCT07499232Phase 3161 sites📍 Dothan📍 Mobile📍 Anaheim Janssen Research & Development, LLC · Tests: Guselkumab, Risankizumab A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease NCT06226883Phase 2225 sites📍 Lancaster📍 San Diego📍 Colorado Springs Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli… · Tests: Placebo, MORF-057 A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease NCT07483099Phase 270 sites📍 Scottsdale📍 Los Angeles📍 Oxnard Eli Lilly and Company · Tests: LY4395089, Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC) Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease NCT06456593Phase 2149 sites📍 Fairhope📍 Scottsdale📍 Sun City Abivax S.A. · Tests: Obefazimod, Placebo A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease NCT06819878Phase 3375 sites📍 Dothan📍 Phoenix📍 Sun City Hoffmann-La Roche · Tests: Afimkibart, Placebo A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease NCT07196722Phase 2, Phase 3372 sites📍 Chandler📍 Litchfield Park📍 Scottsdale Janssen Research & Development, LLC · Tests: Icotrokinra, Placebo A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease NCT06233461Phase 2201 sites📍 Murrieta📍 Orange📍 Clearwater Takeda · Tests: TAK-279, Placebo A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease NCT07577843Phase 3252 sites📍 Anaheim📍 Chula Vista📍 Los Alamitos Janssen Research & Development, LLC · Tests: JNJ-78934804, Guselkumab Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease NCT06754891Phase 130 sites📍 Bengbu📍 Wuwei📍 Guangzhou Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Phar… · Tests: 24mg bid TQH3906 capsule, 32mg TQH3906 capsule, TQH3906 placebo A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease NCT06227910Phase 3138 sites📍 La Jolla📍 Los Angeles📍 Colorado Springs Takeda · Tests: Vedolizumab, Upadacitinib, Placebo A Clinical Trial of Taibowei® Adalimumab Injection in the Treatment of Chinese Pediatric Patients With Moderately to Severely Active Crohn's Disease NCT07564505Phase 41 site📍 Guangzhou Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Tests: Adalimumab Solution for Injection A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008) NCT06430801Phase 3499 sites📍 Dothan📍 Phoenix📍 Sun City Merck Sharp & Dohme LLC · Tests: IV Tulisokibart, SC Tulisokibart, IV Placebo, SC Placebo A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease NCT07184944Phase 3109 sites📍 Colorado Springs📍 Kissimmee📍 Miami Sanofi · Tests: Duvakitug, Placebo PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease NCT05928039Phase 423 sites📍 Calgary📍 Edmonton📍 Vancouver University of Calgary · Tests: TNFa Antagonist - Infliximab, TNFa Antagonist - Adalimumab, Anti-IL12/23 or anti-IL23 - Ustekinumab, Anti-IL12/23 or an… VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease NCT06257706Phase 469 sites📍 Los Angeles📍 Charleston📍 Houston Alimentiv Inc. · Tests: Vedolizumab A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting NCT06581328Phase 4101 sites📍 Birmingham📍 Mobile📍 Chandler Takeda · Tests: Vedolizumab IV, Vedolizumab SC An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With Moderate to Severe Active Crohn's Disease (CD) in Japan NCT06023030n/a104 sites📍 Anjo-shi📍 Handa📍 Nagakute AbbVie Treatment of Chinese Adult Subjects With Moderate to Severe Crohn's Disease With Tabellvi® NCT07663526Phase 47 sites📍 Fuyang📍 Zhengzhou📍 Zhoukou Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Tests: TyboWe® Adalimumab Injection A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease NCT06819891Phase 3208 sites📍 Dothan📍 Glendale📍 Lancaster Hoffmann-La Roche · Tests: Afimkibart, Placebo Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis NCT07697456Phase 265 sites📍 Dothan📍 Phoenix📍 Sun City AbbVie · Tests: Risankizumab, Trosunilimab, ABBV-701 Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight NCT06937099Phase 3183 sites📍 Dothan📍 Anaheim📍 Beverly Hills Eli Lilly and Company · Tests: Mirikizumab, Mirikizumab, Tirzepatide, Placebo A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease NCT07298421Phase 317 sites📍 New York📍 South Brisbane📍 Parkville Hoffmann-La Roche · Tests: Afimkibart A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease NCT05923073Phase 385 sites📍 Los Angeles📍 Hartford📍 Atlanta Janssen Research & Development, LLC · Tests: Guselkumab, Guselkumab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy